LGVN Stock Overview
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Longeveron Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.72 |
| 52 Week High | US$44.00 |
| 52 Week Low | US$1.62 |
| Beta | 0.20 |
| 1 Month Change | -57.27% |
| 3 Month Change | -78.95% |
| 1 Year Change | -93.86% |
| 3 Year Change | -97.18% |
| 5 Year Change | n/a |
| Change since IPO | -97.68% |
Recent News & Updates
Recent updates
Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?
Nov 17
Longeveron Inc.: A New Approach To Treat Alzheimer's
Oct 09Longeveron spikes after FDA’s Fast Track Designation for lead candidate
Aug 31Is Longeveron (NASDAQ:LGVN) In A Good Position To Invest In Growth?
Jul 15Longeveron rises ~20%, co to present Alzheimer's trial abstract at leading conference
Jul 07Longeveron: Small-Cap Biotech Targeting Large Alzheimer's Market
May 06Companies Like Longeveron (NASDAQ:LGVN) Are In A Position To Invest In Growth
Apr 03Longeveron: Speculative Biotech Worth A Look On Rare Disease, Aging, And Alzheimer's Focuses
Feb 15Longeveron: Spooky Social-Media Generated Spike Signifies Nothing
Nov 29Is Longeveron (NASDAQ:LGVN) In A Good Position To Deliver On Growth Plans?
Nov 20Shareholder Returns
| LGVN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -17.7% | 1.0% | 1.2% |
| 1Y | -93.9% | 0.7% | 24.9% |
Return vs Industry: LGVN underperformed the US Biotechs industry which returned 1.1% over the past year.
Return vs Market: LGVN underperformed the US Market which returned 24.7% over the past year.
Price Volatility
| LGVN volatility | |
|---|---|
| LGVN Average Weekly Movement | 28.9% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LGVN's share price has been volatile over the past 3 months.
Volatility Over Time: LGVN's weekly volatility has increased from 18% to 29% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 24 | Mohamed Wa'el Hashad | longeveron.com |
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome.
Longeveron Inc. Fundamentals Summary
| LGVN fundamental statistics | |
|---|---|
| Market cap | US$13.10m |
| Earnings (TTM) | -US$22.21m |
| Revenue (TTM) | US$709.00k |
17.5x
P/S Ratio-0.6x
P/E RatioIs LGVN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LGVN income statement (TTM) | |
|---|---|
| Revenue | US$709.00k |
| Cost of Revenue | US$488.00k |
| Gross Profit | US$221.00k |
| Other Expenses | US$22.43m |
| Earnings | -US$22.21m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.09 |
| Gross Margin | 31.17% |
| Net Profit Margin | -3,132.72% |
| Debt/Equity Ratio | 0% |
How did LGVN perform over the long term?
See historical performance and comparison